WHD wrap up article

World Hemophilia Day 2022 another great success

April 17, 2022 was World Hemophilia Day, and once again, the global bleeding disorders community came together in an inspiring show of solidarity. The theme of the event this year was “Access for All: Partnership. Policy. Progress. Engaging your government, integrating inherited bleeding disorders into national policy”.

Also available in: Français Español

The spirit of engagement this year was clear in the posts and pictures which flooded our social media platforms. Our hashtags were used hundreds of times on social media, and our World Hemophilia Day web page has had almost 22,000 views. Equally inspiring was that 125 buildings and monuments participated in the Light it Up Red campaign—a record despite the ongoing challenges of the COIVD-19 pandemic!

We also saw many people share their stories on our World Hemophilia Day website (don’t forget: you have until the end of the month to submit your own story!). If you haven’t already, read what your peers have posted and take a moment to “like” a post to show your support.

Hundreds of messages from the community were posted on Facebook, Twitter and LinkedIn on April 17. While we can’t share all of them with you, here are some we think you might like to read (click on the images to see the original posts).

And, of course, the WFH posted on the big day as well. Here are two posts which were popular (click on the images to see the original posts).

On behalf of the WFH and everyone in the bleeding disorders community, thank you for your support on World Hemophilia Day. The ongoing COVID-19 pandemic has been very tough on the bleeding disorders community, and the fact that World Hemophilia Day was such a success is proof of our resilience, dedication, and community spirit.

To learn more about World Hemophilia Day, please click here.

The WFH would like to thank our 2022 World Hemophilia Day sponsors for their continued support: Bayer, BioMarin Pharmaceutical Inc., Biotest, CSL Behring, F. Hoffman-La Roche Ltd., Freeline Therapeutics, GC Pharma, Grifols, Kedrion, LFB S.A, Novo Nordisk, Octapharma, Pfizer, Sanofi, Sobi, Spark Therapeutics, and Takeda.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.